Boehringer Ingelheim International Gmbh

Shuang Liang

Qiang Zhang

Michael Robert Turner

Renee M Zindell

Dieter Wiedenmayer

Robert Owen Hughes

Xiang Li

Todd Bosanac

Darren Todd Disalvo

Joshua Courtney Horan

Robert Sibley

Lifen Wu

Angela Kay Berry

Michael Jason Burke

Joerg Bentzien

Yue Shen

Johanna Bakonyi

Thomas Martin Kirrane, Jr

Zhaoming Xiong

Lana Louise Smith Keenan

Can Mao

Brian Nicholas Cook

Steven Richard Brunette

Alexander Heim-Riether

Ingo Andreas Mugge

Fariba Soleymanzadeh

Anil Kumar Padyana

Bernd Wellenzohn

Wang Mao

Delphine Collin

Sabine K Schlyer

Steven John Taylor

Neil Alexander Farrow

Celina Lasota

Joerg Martin Bentzien

Donghong A Gao

The present invention encompasses compounds of the formula (I) wherein the groups A, Cy, X1 and Y are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.

Heteroaromatic compounds as BTK inhibitors

The present invention encompasses compounds of the formula (I): wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them. 

Compounds as modulators of RORC

The present invention encompasses compounds of the formula (I), wherein the variables are defined herein which are suitable for the modulation of RORC and the treatment of diseases related to the modulation of RORC. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them. 

The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of ROR&#x3b3; and the treatment of diseases related to the modulation of ROR&#x3b3;. The present invention also encompasses processes of making compounds of formula (I) and pharmaceutical preparations containing them.

Compounds as modulators of ROR&#x3b3;

The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof, wherein A, A, A, L, Land D are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene Ahydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the Compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds. 

Arylpyrazole ethers as inhibitors of leukotriene A4 hydrolase

The present invention encompasses compounds of the formula (I) wherein the groups X and Cy are defined herein, which are suitable for the treatment of diseases related to BTK, process of making, pharmaceutical preparations which contain compounds and their methods of use.

Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I. 

Fused heteroaryl diamide compounds useful as MMP-13 inhibitors

Growing community of inventors

Roseville, MN, United States of America

Shuang Liang